Introduction

IJO

International Journal of Oncology

1019-6439 1791-2423

D.A. Spandidos

10.3892/ijo.2023.5540

IJO-63-2-05540

Articles

Deactivation of glycogen synthase kinase-3β by heat shock‑inducible tumor small protein attenuates hyperthermia‑induced pro‑migratory activity in colorectal cancer cells

Koizumi

Keita

1 Domoto

Takahiro

2 Minamoto

Toshinari

2 Satomura

Kazuhito

3 Nakajima

Hideo

1 2 4

1Department of Oncology, Ageo Central General Hospital, Ageo, Saitama 362-8588, Japan 2Divison of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa 920-0934, Japan 3Department of Oral Medicine and Stomatology, Tsurumi University School of Dental Medicine, Yokohama, Kanagawa 230-8501, Japan 4Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama 350-8550, Japan

Correspondence to: Dr Hideo Nakajima or Dr Keita Koizumi, Department of Oncology, Ageo Central General Hospital, 1-10-10 Kashiwaza, Ageo, Saitama 362-8588, Japan, E-mail: koizumi.ke@ach.or.jp nakajima.h@ach.or.jp

08 2023

23 06 2023

63 2

01062022 20042023

2023

Hyperthermia is a promising approach for improving cancer treatment in combination with chemotherapy, radiotherapy and/or immunotherapy; however, its molecular mechanisms remain unclear. Although heat shock proteins (HSPs) are involved in hyperthermia via antigen presentation and immune activation, major HSPs including HSP90 are associated with cancer progression via tumor cell migration and metastasis. The present study showed that heat shock-inducible tumor small protein (HITS) could counteract the pro-migratory effects of HSPs in colorectal cancer (CRC) cells, which represents a novel function. Western blotting analysis revealed that overexpression of HITS increased the protein level of glycogen synthase kinase-3β (GSK3β) phosphorylated (p) at the serine 9 (pGSK3β^S9; inactive form) in HCT 116, RKO and SW480 CRC cells. GSK3β^S9 phosphorylation was reported to suppress migration in some cancer types; therefore, by using the wound healing assay, the present study revealed that HITS overexpression decreased the migration activity of CRC cells. Induction of HITS transcription was observed at 12 and 18 h after heat shock (HS) by using semi-quantitative reverse transcription-PCR analysis, followed by increased levels of pGSK3β^S9 protein at 24 and 30 h in CRC cells in western blotting. Thus, HS induced not only HSPs to promote cell migration, but also HITS to counteract the migratory activity of these HSPs in CRC cells. HITS knockdown in CRC cells subject to HS showed increased cell migration in wound healing assay, which was decreased by the GSK3β inhibitor AR-A014418, confirming the anti-migratory effect of HITS via the deactivation of GSK3β. The present findings indicated that the deactivation of GSK3β sufficiently offset the pro-migratory effect of hyperthermia via major HSPs in CRC.

hyperthermia colorectal cancer heat shock-inducible tumor small protein (HITS) glycogen synthase kinase-3β heat shock protein 90 migration

Extramural Collaborative Research Grant of Cancer Research Institute

Kanazawa University

Ageo Central General Hospital

This study was supported in part by the Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University. This study was also supported by a fund from Ageo Central General Hospital.

Introduction

Colorectal cancer (CRC) is the third most commonly diagnosed cancer type and the second leading cause of cancer-related deaths worldwide (1,2). Patients with CRC develop metastatic disease in >50% of cases, especially in the liver, which results in the death of >2/3 of the patients (3–5). Advances in chemotherapy, radiotherapy and immunotherapy have improved the survival of patients with metastatic CRC (6,7); however, resistance to anticancer drugs, radiation and immune therapies remains a major therapeutic challenge (7–9).

Increasing evidence has demonstrated that the combination of hyperthermia with the aforementioned therapies can overcome tumor resistance to antitumor treatments and improve their efficacy (10–12). In addition, heat shock (HS) proteins (HSPs) are involved in enhancing the cytotoxic activity of natural killer (NK) cells (11,13), inducing maturation and antigen presentation of dendritic cells and activating T-cells (11,14). By contrast, previous studies have indicated that HSPs including HSP90 promote cancer cell proliferation, invasion and metastasis, as well as tumor angiogenesis, which can negatively affect the hyperthermia efficacy (15,16). These major HSPs are highly expressed in some malignant tumor types and are inversely correlated with prognosis, leading to these HSPs being used as therapeutic targets (15,16). Nonetheless, the overall involvement of HSPs in hyperthermia remains unclear.

Heat shock-inducible tumor small protein (HITS) is an 18 kDa protein that was originally identified as a molecule upregulated upon HS treatment in Jurkat cells (17). The induction of HITS protein as well as HSP90 protein has been confirmed in THP-1 cells in vitro and transplanted rat walker 256 sarcoma cells in vivo (17). HITS is highly homologous to downregulated in renal cell carcinoma 1 (DRR1), a putative tumor suppressor that plays important roles in actin and microtubule cytoskeleton organization, and is downregulated in renal cell carcinoma (17–19). Our previous studies indicate that HITS expression can be observed in various cancer cells and is downregulated during tumor progression in colon cancer as well as cervix, thyroid and breast cancers compared with the corresponding healthy tissues (17,20). Unlike the major HSPs, overexpression of HITS shows tumor suppressive phenotype in the mouse cervical cancer xenograft model (20).

The present study showed that HITS overexpression increased the levels of glycogen synthase kinase-3β (GSK3β) phosphorylated (p) at serine (S) 9 (pGSK3β^S9), resulting in its deactivation in CRC cells (21–23). To the best of our knowledge, while GSK3β deactivation has been reported to prevent β-catenin degeneration (23), no previous studies have shown a direct association of cellular GSK3β deactivation with cancer development or progression (22). GSK3β does not participate in the canonical β-catenin destruction complex in the majority of CRCs due to the mutations in either adenomatous polyposis coli (APC; <90% of cases), catenin β-1 (CTNNB1; ~5% of cases) or axis inhibition protein 1 (AXIN1) (22). By contrast, previous studies have demonstrated that pharmacological inhibition of GSK3β activity suppresses cancer progression by attenuating tumor cell migration and invasion in several cancer types, including colorectal, breast and pancreatic cancers, in addition to glioblastoma (21–29). The present study showed that HITS upregulation induced by HS exerted an anti-migratory effect via GSK3β deactivation (S9 phosphorylation) in human CRCs, thereby counteracting the pro-migratory effects of HSPs. This novel anti-migratory mechanism may play an important role in reducing the risk of cancer metastasis during hyperthermia.

Materials and methods <sec> <title>Cell culture

HCT 116, RKO and SW480 cells were purchased from American Type Culture Collection and maintained in Dulbecco's Modified Eagle's Medium-high glucose (cat. no. 043-30085; Fujifilm Wako Pure Chemical Corporation) supplemented with 10% fetal bovine serum (FBS) (cat. no. F7524; Sigma-Aldrich; Merck KGaA) in a humidified incubator with 5% CO₂ at 37°C. Cells were tested for mycoplasma contamination.

Western blotting

Cells were lysed with 2X sample buffer containing 4% SDS (cat. no. 08933-34; Nacalai Tesque, Inc.), 20% glycerol (cat. no. 17018-25; Nacalai Tesque, Inc.), 0.001% bromophenol blue (cat. no. 05808-61; Nacalai Tesque, Inc.), 0.125 M Tris HCl (cat. no. T1503, Sigma-Aldrich; Merck KGaA) and 10% 2-mercaptoethanol (cat. no. 21418-42; Nacalai Tesque, Inc.) and boiled for 5 min. The protein concentration was measured using BCA Protein Assay Kit (cat. no. 23225; Thermo Fisher Scientific, Inc.). Lysates (20 µg/lane) were separated by SDS-PAGE on an 8.5% gel and transferred onto PVDF membrane (cat. no. IPVH00010; MilliporeSigma). To calculate relative intensity, cell lysates to compare were loaded in the same gel. Membranes were blocked with phosphate-buffered saline [PBT; 0.01 M Na₂HPO₄; cat. no. 31801-05 and KH₂PO₄; cat. no. 28721-55; pH 7.4 with 0.15 M NaCl; cat. no. 31320-05; and 0.1% Tween-20 (cat. no. 35624-02; Nacalai Tesque, Inc.)] containing 5% non-fat dry milk or 5% bovine serum albumin (cat. no. 019-21272; Fujifilm Wako Pure Chemical Corporation) for 1 h at room temperature. After washing with PBT, the membranes were incubated with the primary antibodies against GSK3β (1:20,000 or 40,000; cat. no. 9315; Cell Signaling Technology, Inc.), pGSK3β^S9 (1:1,000 or 2,000; cat. no. 9336; Cell Signaling Technology, Inc.) and β-tubulin (1:120,000 or 40,000; cat. no. 017-25031; Fujifilm Wako Pure Chemical Corporation) overnight at 4°C. This was followed by incubation with anti-rabbit (1:4,000 dilution; cat. no. 5220-0336; SeraCare Life Sciences, Inc.) and anti-mouse (1:4,000 dilution; cat. no. 5220-0341; SeraCare Life Sciences, Inc.) horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. The protein bands were developed using the ECL Prime Western Blotting Detection Reagent (cat. no. RPN2232; Cytiva) and the chemiluminescence was detected using a ChemiDoc Touch MP Imaging System with Image Touch 2.4 software (Bio-Rad Laboratories, Inc.) or C-Digit Blot scanner (LI-COR Biosciences).

RNA extraction and semi-quantitative reverse transcription (RT)-PCR

Total RNA was extracted from cells using TRIzol™ (cat. no. 15596026; Thermo Fisher Scientific, Inc.) and reverse-transcribed to complementary DNA (cDNA) using ReverTra Ace™ (cat. no. FSQ-201; Toyobo Life Science) with Random Primer (cat. no. FSK-301; Toyobo Life Science) according to the manufacturer's instructions. Semi-quantitative RT-PCR was performed using a LifeECO thermal cycler (Yakukensha Co., Ltd.). The reaction mixture comprised 0.25 µl Blend Taq plus (2.5 U/µl; cat. no. BTQ-201; Toyobo Life Science), 2.5 µl 10X buffer, 2.5 µl dNTP (2 mM; cat. no. NTP-501; Toyobo), 0.25 µl primers (10 µM; cat. no. FSK-301; Toyobo) and 1–3 µl of synthesized cDNA. The following primer pairs were used for semi-quantitative RT-PCR: HITS forward, 5′-CCACCTGAGGATATTGACCATAA-3′ and reverse, 5′-TTCTGTGCTTCTTCTTCCTTCTG-3′; matrix metalloproteinase-3 (MMP-3), forward, 5′-CTCAGGAAGCTTGAACCTGAAT-3′ and reverse, 5′-CAGCTCGTACCTCATTTCCTCT-3′; MMP-13, forward, 5′-TTACCAGTCTCCGAGGAGAAAC-3′ and reverse, 5′-TTTTGGAAGACCCAGTTCAGAT-3′; and TATA-box binding protein (TBP) forward, 5′-AGAAAGTGAACATCATGGATCAGA-3′ and reverse, 5′-GTTTACAACCAAGATTCACTGTGG-3′. TBP was amplified as an internal control to normalize the expression of the target gene. The PCR reaction was performed under the following conditions: Initial denaturation at 94°C for 1 min; followed by cycling at 94°C for 20 sec, 55°C (HITS, MMP-13 and TBP) or 53°C (MMP-3) for 20 sec and 72°C for 20 sec; and final extension at 72°C for 1 min. The numbers of cycles were 29 and 30 for HITS, TBP; 36 for MMP-3, 36 for MMP-13 and 33 for TBP. The DNA products were run on a 1.2% agarose gel containing ethidium bromide (cat. no. 312-01193; Nippon Gene Co., Ltd.) and imaged using a ChemiDoc MP Imaging System (Bio-Rad Laboratories, Inc.). The intensity of each band was quantified using ImageJ software, ver. 1.50 (National Institutes of Health).

Plasmid construction and overexpression

The amino acid sequence of the mouse HITS open reading frame (ORF) is 98.47% homologous to the human HITS; therefore, mouse HITS ORF was cloned for transfection (17). The HITS ORF fragment with EcoRV and BamHI ends was amplified from HeLa-Tet-HITS (16) using PCR (initial denaturation at 94°C for 1 min; 25 cycles of 94°C for 20 sec, 55°C for 20 sec and 72°C for 20 sec; and a final extension at 72°C for 1 min) and the following primers: forward, 5′-GATATCATGGCTGAGCCAGACTACATAGAAG-3′, and reverse, 5′-GGATCCCTAGGACTCCTGGGCCTGAGCCACC-3′. The amplified DNA was cloned into PCR2.1 vector using the TOPO™ TA™ Cloning Kit (cat. no. K450002; Thermo Fisher Scientific, Inc.) and subcloned into the EcoRV/BamHI sites of pCAG-IRES-EGFP, which was kindly supplied by Dr T. Kawauchi (30). The generated plasmid (0.5 µg/well), namely pCAG-HITS-IRES-EGFP, and pEGFP (30) were mixed with transfection reagents and kept for 10 min then transfected into HCT 116, RKO and SW480 cells, using Lipofectamine 3000^™ (cat. no. L3000001; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. The cells were incubated for 36 h and obtained cell lysates for western blotting, wound healing assay or MTT assay as described later. Transfection efficiency was tested using semi-quantitative RT-PCR as described in the previous section (Fig. S1).

RNA interference (RNAi)

The sequences of small interfering RNAs (siRNAs) targeting HITS were as follows: HITS-siRNA#1, 5′-GGAUAUUGACCAUAAGGACUCAUAU-3′; and HITS-siRNA#2, 5′-GCCUCAGAAACUGAUCAAUCCUGUA-3′ (Thermo Fisher Scientific, Inc.). Lipofectamine™ RNAiMAX (cat. no. 13778030; Thermo Fisher Scientific, Inc.) was used to transfect HITS siRNAs and control siRNA (cat. no. 12935300; Thermo Fisher Scientific, Inc.). A total of 10 pmol/well siRNAs were mixed with transfection reagents and kept for 5 min according to the manufacturer's instructions. The cells were incubated for 36 h and obtained cell lysates for western blotting or wound healing assay as described later.

Wound healing assay

HCT 116 cells were seeded at a density of 5×10⁵ cells/well in a 24-well plate and transfected with HITS the following day. At 10 h after transfection, the cells were trypsinized, re-seeded at a density of 8×10⁵ cells/well, and incubated for 18 h (the confluency of the cells reached 80–90%). The cells were then scratched with a 200-µl pipette tip and the medium was replaced to medium containing 1% FBS to prevent the loose cells from settling back down. Images of the cells were captured at 0 and 24 h under a phase-contrast and fluorescence microscope (BZ-X700; Keyence Corp.). Multiple images were captured with the microscope to cover an entire scratched area and merged into one image to compare the same wound gap positions between 0 and 24 h. The wound healing rate was calculated as follows: Wound healing rate (%)=(wound area at 0 h-wound area at 24 h)/(initial wound at 0 h) ×100. For the assay performed on HS-induced cells (HS at 42°C for 1 h), 8.5×10⁵ cells/well were plated. For RNAi followed by HS and inhibitors treatment, the CytoSelect 24-well Wound Healing Assay Kit (Cell Biolabs, Inc.) was used. Plastic inserts provided with the kit were placed onto the wells to create wound gaps where cells were plated at a density of 8.5×10⁵ cells/well. Some groups of cells were treated with the HSP90 inhibitor 17-AAG (cat. no. CS-0161; Funakoshi Co., Ltd.) or the GSK3β inhibitor AR-A014418 (cat. no. A3230; Sigma-Aldrich; Merck KGaA), both of which were dissolved in dimethyl sulfoxide (DMSO) to prepare 10 mM stock solutions. DMSO was added to control and 17-AAG samples to adjust the DMSO concentration to 0.2%. The concentration of 17-AAG was optimized by testing different concentrations, which showed suppression of cell migration but no effect against cell survival (data not shown). The concentration of AR-A014418 was determined based on our previous studies (29).

MTT assay

HCT 116 cells were seeded at a density of 1×10⁴ cells/well in a 96-well plate. The expression vectors pCAG-HITS-IRES-EGFP and pEGFP were transfected into the cells the following day, as previously described. The MTT assay (cat. no. 11465007001; Sigma-Aldrich; Merck KGaA) was performed 2 days after transfection, according to the manufacturer's instructions. Methanol was used to dissolve formazan. Colorimetric detection was done at a wavelength of 550 nm and reference wavelength was 690 nm.

Statistical analysis

Data are expressed as the mean ± standard error. Statistical analysis was performed using the unpaired Student's t-test to compare two groups of data and one-way analysis of variance (ANOVA) followed by Dunnett's test or two-way ANOVA followed by Tukey's test for multiple comparisons. P<0.05 was considered to indicate a statistically significant difference.

Results <sec> <title>HITS promotes the phosphorylation of GSK3β S9 in CRC cells

The effects of HITS on GSK3β, which plays important roles in tumorigenesis (21,22), were investigated to study the role of HITS in cancer progression. Overexpression of HITS in HCT 116, RKO and SW480 cells were followed by a significant increase in pGSK3β^S9 level, while no significant changes were observed in the expression of GSK3β (Fig. 1A-C) nor in the levels of GSK3β phosphorylation at tyrosine (Y)216 (pGSK3β^Y216; active form; data not shown).

HCT 116 is one of the human CRC cell lines that were established to extrapolate clinical CRC (31,32). Our previous studies showed the distinct and common tumor-promoting roles of active GSK3β (lower and higher phosphorylation of its S9 and Y216 residues, respectively) in multiple human CRC cell lines including HCT 116 cells (29,33–35). In addition, no biological association between the pathological (tumor-promoting) property of deregulated GSK3β and the pathways mediated by activated β-catenin and phosphoinositide 3-kinase (PI3K)/Akt in human CRC cell lines including HCT 116 cells as well as in clinical CRC tumors (29). Therefore, the present study used HCT 116 cells for the subsequent analyses.

To confirm the effects of HITS on the expression and phosphorylation of GSK3β, HITS RNAi was performed on CRC cells. Semi-quantitative RT-PCR indicated that transfection with either HITS siRNA#1 or HITS siRNA#2 significantly reduced HITS mRNA expression by >90% compared with the that in cells transfected with control siRNA (Fig. S2). Transfection of these HITS siRNAs in HCT 116 cells significantly decreased the level of pGSK3β^S9 compared with that in cells transfected with control siRNA, but did not affect the GSK3β expression (Fig. 1D-F). The present data demonstrated that HITS promoted the phosphorylation of GSK3β at S9 in CRC cells.

HS induces GSK3β S9 phosphorylation via HITS upregulation

Our previous study showed that HS induced HITS protein expression both in vitro and in vivo (17). To study the transcriptional response to HS in detail, the levels of HITS mRNA were monitored in HCT 116 cells in response to HS (42°C, 1 h). Semi-quantitative RT-PCR analysis showed that the level of HITS mRNA increased relatively slowly following HS, with its expression peaking at 12 h after HS (Fig. 2A). The level of pGSK3β^S9 in the cells, measured using western blotting, increased significantly at 24 and 30 h after HS compared with their respective controls (Fig. 2B and C). This was likely caused by HITS upregulation in response to HS, since HITS knockdown in the heat-shocked cells significantly decreased the level of pGSK3β^S9 at 24 h after HS compared with the control group (Fig. 2E and F). Significantly increased expression of GSK3β was observed 18 h after HS compared with the control (Fig. 2B and D); however, HITS knockdown induced no significant change in the GSK3β expression (Fig. 2E and G).

HITS suppresses cell migration but not proliferation

It is hypothesized that HITS is involved in suppressing tumor progression via phosphorylation-dependent deactivation of GSK3β. To investigate the effects of HITS on the migration of CRC cells, a wound healing assay was performed on HCT 116 cells transfected with a pEGFP control vector expressing GFP or pCAG-HITS-IRES-EGFP vector expressing both HITS and GFP. Compared with that in the control cells, cells overexpressing HITS showed a significant suppression of cell migration (Fig. 3A and B). This was not due to a cell proliferation suppression caused by HITS because no significant changes were observed in cell proliferation upon HITS overexpression (Fig. 3C).

MMPs are key proteases involved in cancer cell migration, invasion and metastasis by degrading the extracellular matrix (ECM) (36). MMP-3 and MMP-13 have been reported to be regulated by GSK3β (37); therefore, the present study investigated if HITS caused any changes in the expression of MMPs. Semi-quantitative RT-PCR and western blotting analysis revealed significant downregulation of MMP-3 and MMP-13 mRNA and protein in the HITS overexpressing cells (Fig. 3D-F), indicating that HITS suppressed cell motility, at least in part, by downregulating MMP-3 and MMP-13.

Anti-migratory effect of the HITS-GSK3β pathway offsets the pro-migratory effects of HSPs after HS

Previous studies have indicated that, while HS increases HITS expression, HS also induces expression of HSPs, including HSP90 (17,38,39), which in turn promotes the migration of cancer cells (15,16,40–42). Therefore, it remains unclear whether the overall effects of HS on CRC cell migration are promotive or suppressive. Thus, a wound healing assay was performed to compare the migration of cells with and without HS. To cover all the time points where the S9 phosphorylation or the protein expression of GSK3β was upregulated by HS, HCT 116 cells were scratched and observed at 14 and 38 h (0 and 24 h in the wound healing timeframe, respectively) after HS. No significant change was observed in the migration of these cells (Fig. 4A), suggesting that the anti-migratory effect of the HITS-GSK3β pathway offset the pro-migratory activities of HSPs after HS. To understand the HITS-GSK3β effect, HITS siRNAs were transfected into HCT 116 cells under the same HS conditions, and a wound healing assay was performed following the time schedule shown in Fig. 4B. The wound healing rate was significantly increased in cells transfected with HITS siRNAs compared with that in the control, demonstrating that HITS decreased the migration of the cells induced with HS (Fig. 4C and D). Subsequently, the pro-migratory effect of HSP90 was further demonstrated using 17-AAG which is metabolized by NAD(P)H:quinone oxidoreductase 1 (NQO1) and selectively inhibits HSP90 (43). 17-AAG decreased the wound healing rate of HS-treated cells (Fig. 4C and D). Moreover, the migratory effect of the HITS knockdown was not observed in cells treated with 17-AAG, which suggested that the pro-migratory pathway mediated by HSP90 was the target of HITS. The function of HITS was mediated by GSK3β because the treatment with the specific GSK3β inhibitor, AR-A014418 (44) counteracted the effects of the HITS knockdown on cell migration (Fig. 4C and D). Taken together, the present findings indicated that HS not only induced the pro-migratory pathways mediated by HSPs, but also induced the anti-migratory pathway involving HITS and GSK3β, and that HITS-mediated GSK3β deactivation sufficiently offset the pro-migratory activity in CRC cells.

Discussion

The present study explored the effects of HS on CRC cell migration by focusing on HITS and its putative downstream target GSK3β. The level of pGSK3β^S9 (GSK3β inactive form) was significantly increased in CRC cells overexpressing HITS, whereas its knockdown showed an opposite effect. These data demonstrated that HITS expression suppressed GSK3β activity by increasing the levels of pGSK3β^S9. Our previous studies have indicated that the deactivation of GSK3β by S9 phosphorylation suppresses tumor progression in various CRC cells such as RKO, SW480, SW48, SW620 and HT29, as well as HCT 116 in vitro (29) and xenograft in vivo (35). The wound healing assay showed that overexpression of HITS in the CRC cells significantly suppressed cell migration compared with that of the control cells. This was most likely mediated by GSK3β deactivation because the positive effect of HITS knockdown on cell migration was abolished by treatment with the GSK3β inhibitor AR-A014418.

The molecular mechanisms underlying the anti-migratory and anti-invasive effects of GSK3β inhibition are of interest. Previous studies have indicated that the inhibition of GSK3β suppresses F-actin assembly and decreases the formation of lamellipodia and invadopodia via suppression of the phosphorylation-dependent activity of focal adhesion kinase (FAK) (27,28,45), c-Jun N-terminal kinase (JNK) (27) and adenylyl cyclase-associated protein 1 (CAP1) (46,47), the deactivation of guanine nucleotide-exchange factors (GEF) and Ras-related C3 botulinum toxin substrate 1 (RAC1) (27,28,48) and the degradation of nuclear factor of activated T cells (NFAT) (49). Potential involvement of these functional molecules in suppression of CRC cells migration upon the S9 phosphorylation-mediated deactivation of GSK3β is an aim of our future studies to investigate mechanisms by which HITS regulates tumor cell migration. The deactivation of GEF/RAC1 and JNK pathways reduces the expression of MMP-2 and membrane type 1 (MT1)-MMP, resulting in the suppression of invadopodia formation in glioblastoma and pancreatic cancer cells (27,28). The present study showed that HITS decreased the expression of MMP-3 and MMP-13 in CRC cells in association with attenuated cell migration (50,51). Therefore, the anti-migratory effect of HITS in cancer cells might be mediated by suppressing these MMPs.

A previous study reported that DRR1, which shares a highly homologous region with HITS but is not induced by HS (18,19,52), can directly bind actin (53). This study elucidated the two actin-binding regions of DRR1, of which the N-terminal region is highly homologous to HITS (70% amino acid identity) and is necessary for suppressing F-actin elongation in HeLa cells. It is possible that HITS also directly binds to actin to suppress F-actin assembly. Guo et al (54) indicated that the downregulation of HITS by S100A4, a pro-metastatic protein, increases the migration of gastric cancer MGC803 cells. Considering that S100A4 has been reported to bind F-actin and myosin II heavy chain to promote cytoskeletal formation (55,56), the direct binding of HITS to actin may disturb the interaction between S100A4 and the actin/myosin II heavy chain, resulting in the suppression of cell migration. In conjunction with these previous studies, the present findings suggested that HITS was involved in suppressing actin cytoskeleton formation directly and/or via S9 phosphorylation-mediated deactivation of GSK3β, which suppresses the formation of lamellipodia and invadopodia to prevent the CRC cell migration that is necessary for invasion (Fig. 5).

A number of previous studies have indicated that HSPs promote the migration, invasion and metastasis of cancer cells (15,16,57–59). Among the HSPs, HSP90 was shown to act as a molecular chaperone able to stabilize and maintain oncoproteins involved in CRC progression such as mutated TP53 (gain-of-function), HER2 and BRAF, especially in stress conditions caused by chemotherapy, radiotherapy and hyperthermia (60,61). GSK3β has also been shown to be one of the client proteins of HSP90 (62–64), which in turn phosphorylates HSP90 and HSP70 to facilitate cancer progression (65). The upregulation of HSP90 in HCT 116 cells was indicated in a previous report (66). Consistently, the increased expression of GSK3β observed after HS might be due to the chaperoning function of HSP90 and other HSPs. It has been indicated that HSP90 chaperoning function is required for maintaining the expression and/or function of FAK, NFAT, JNK and MMPs (67–71) that promote the cell migration under the control of GSK3β, as discussed above. The present study indicated that GSK3β was involved in the major pro-migratory pathways mediated by HSP90 after HS, and that the inhibition of GSK3β caused by HITS played a critical role in attenuating the pro-migratory effect of GSK3β (Fig. 5). Indeed, HS did not induce significant changes in the migration of HCT 116 cells, although HSP90 was activated and showed pro-migratory activity. This was most likely due to the deactivation of GSK3β caused by HITS because HITS knockdown, under the same HS condition, showed an increase in wound healing rate, which in turn was decreased by treatment with AR-A014418. Treatment with 17-AAG counteracted the effect of the HITS knockdown, confirming the HSP90 chaperoning effect on GSK3β and its downstream pathways (Fig. 5). Other studies have also reported the anti-migratory and anti-metastatic effects of hyperthermia in vitro or in animal models, although the underlying mechanisms remain unclear (72–74). In these reports, the HITS-GSK3β pathway might have played a critical role in suppressing cell migration in these reports.

The single or combined use of HSPs inhibitors with other therapies were proposed as attractive strategies for cancer therapy (75,76). Several studies have proposed to use hyperthermia in combination with HSP inhibitors, such as HSP90 inhibitors, which provides successful in vitro results (77–79). However, HSPs are involved in the activation of the immune response, including the cytotoxicity of NK cells, maturation and antigen presentation of dendritic cells, and activation of T cells (11,13,14). Previous studies have shown that CRC is a heterogeneous disease consisting of the right-side colon cancer and the left-side colorectal cancer with different molecular, biological and clinicopathological properties (80–82). Consistently, the antitumor immunity activated by HSPs would be beneficial to prevent peritoneal metastasis of the right-sided (proximal) colon cancer with highly immunogenic and intensive lymphocytic infiltration (81,82). Therefore, the combined use of HSPs inhibitors with hyperthermia may reduce the clinical benefits of hyperthermia. The present findings showed that the HITS-GSK3β pathway prevented hyperthermia-induced cancer cell migration caused by HSP90. One concern of the present study is that, in certain cancer types, HS may not induce HITS considering that the endogenous HITS expression has been reported to be suppressed in various cancer types (17,20,83,84) possibly due to epigenetic modification (84–86). The present data showed that treatment with a GSK3β inhibitor reinforced the anti-migratory effect via HITS, while other studies also showed the benefit of GSK3β inhibitors to activate NK cells and dendritic cells and suppress the immune checkpoint protein PD-1 to enhance CD8⁺ T cells activity (87–90). Grassilli et al (91) also indicated another benefit of GSK3β inhibitors to overcome drug resistance of p53 null colon carcinoma by inducing necroptosis. Accordingly, as well as an investigation of the putative roles of the pathways mediated by HITS and GSK3β in CRC biology as discussed in the former paragraph, the combination use of GSK3β inhibitors with hyperthermia would be an aim of our future studies.

Hyperthermia in cancer treatment shows clinical benefits because of its antitumor effects exerted through several processes, such as direct heat-induced cell death, induction of oxidative stress and molecular damage, antitumor immunity boosting, radio- and chemo-sensitivity enhancement, tumor microenvironment modifications, and inhibition of epithelial-to-mesenchymal transition (10–14). While the HSF1-HSPs system, major cellular responses to HS, has long been considered to have a promigratory function that leads to cancer progression, the present study clarified that HITS could counterbalance the migratory effects caused by major HSPs (15,16), such as HSP90 in CRC cells. Further investigation is required to fully understand the molecular mechanisms underlying the antitumor effects of hyperthermia.

Supplementary Material

Supporting Data

Acknowledgements

The authors thank Dr Keiko Nakao (Saitama Medical University, Moroyama, Japan) for providing DNA vectors and technical support.

Availability of data and materials

The datasets used and/or analyzed during of current study are available from the corresponding author on reasonable request.

Authors' contributions

KK conceptualized the study, designed the experiments, acquired data and wrote the primary manuscript. TD acquired data and resources, designed the methodology and critically revised and proofread the manuscript. TM and KS acquired resources, designed methodology and critically revised and proofread the manuscript. HN conceptualized the study, acquired resources, designed methodology and critically revised and proofread the manuscript. All authors read and approved the final version of the manuscript. KK and HN confirm the authenticity of all the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Bray

Ferlay

Soerjomataram

Siegel

Torre

Jemal

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

CA Cancer J Clin683944242018

10.3322/caac.21492

30207593

Sung

Ferlay

Siegel

Laversanne

Soerjomataram

Jemal

Bray

Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

CA Cancer J Clin712092492021

10.3322/caac.21660

33538338

Leporrier

Maurel

Chiche

Bara

Segol

Launoy

A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer

Br J Surg934654742006

10.1002/bjs.5278

16523446

Zarour

Anand

Billingsley

Bisson

Cercek

Clarke

Coussens

Gast

Geltzeiler

Hansen

Colorectal cancer liver metastasis: Evolving paradigms and future directions

Cell Mol Gastroenterol Hepatol31631732017

10.1016/j.jcmgh.2017.01.006

28275683

Dillekås

Rogers

Straume

Are 90% of deaths from cancer caused by metastases?

Cancer Med8557455762019

10.1002/cam4.2474

31397113

Chow

Chok

Colorectal liver metastases: An update on multidisciplinary approach

World J Hepatol111501722019

10.4254/wjh.v11.i2.150

30820266

Ganesh

Stadler

Cercek

Mendelsohn

Shia

Segal

Diaz

Immunotherapy in colorectal cancer: rationale, challenges and potential

Nat Rev Gastroenterol Hepatol163613752019

10.1038/s41575-019-0126-x

30886395

Van der Jeught

Drug resistance and new therapies in colorectal cancer

World J Gastroenterol24383438482018

10.3748/wjg.v24.i34.3834

30228778

George

Franke

Chakravarthy

Das

Dasari

El-Rayes

Hong

Kinsella

Landry

Lee

National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer

Cancer125273227462019

31017664

Hettinga

Konings

Kampinga

Reduction of cellular cisplatin resistance by hyperthermia-a review

Int J Hyperthermia134394571997

10.3109/02656739709023545

9354931

Yagawa

Tanigawa

Kobayashi

Yamamoto

Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery

J Cancer Metastasis Treat32182302017

10.20517/2394-4722.2017.35

Vassos

Piso

Metastatic colorectal cancer to the peritoneum: Current treatment options

Curr Treat Options Oncol19492018

10.1007/s11864-018-0563-8

30173342

Dayanc

Beachy

Ostberg

Repasky

Dissecting the role of hyperthermia in natural killer cell mediated anti-tumor responses

Int J Hyperthermia2441562008

10.1080/02656730701858297

18214768

Tsan

Gao

Heat shock proteins and immune system

J Leukoc Biol859059102009

10.1189/jlb.0109005

19276179

Ciocca

Calderwood

Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications

Cell Stress Chaperones10861032005

10.1379/CSC-99r.1

16038406

Boroumand

Saghi

Avan

Bahreyni

Ryzhikov

Khazaei

Hassanian

Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives

J Pharm Pharmacol701511582018

10.1111/jphp.12824

28980313

Nakajima

Ishigaki

Xia

Ikeda

Yoshitake

Yonekura

Nojima

Tanaka

Umehara

Tomosugi

Induction of HITS, a newly identified family with sequence similarity 107 protein (FAM107B), in cancer cells by heat shock stimulation

Int J Oncol375835932010

10.3892/ijo_00000707

20664927

Liu

Zhao

Bai

Liang

Nie

Yuan

Wang

Chen

Wei

Induction of tumor inhibition and apoptosis by a candidate tumor suppressor gene DRR1 on 3p21.1

Oncol Rep22106910752009

19787223

Schmidt

Schülke

Liebl

Stiess

Avrabos

Bock

Wochnik

Davies

Zimmermann

Scharf

Tumor suppressor down-regulated in renal cell carcinoma 1 (DRR1) is a stress-induced actin bundling factor that modulates synaptic efficacy and cognition

Proc Natl Acad Sci USA10817213172182011

10.1073/pnas.1103318108

21969592

Nakajima

Koizumi

Tanaka

Ishigaki

Yoshitake

Yonekura

Sakuma

Fukushima

Umehara

Ueno

Loss of HITS (FAM107B) expression in cancers of multiple organs: Tissue microarray analysis

Int J Oncol41134713572012

10.3892/ijo.2012.1550

22825356

Domoto

Pyko

Furuta

Miyashita

Uehara

Shimasaki

Nakada

Minamoto

Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy

Cancer Sci107136313722016

10.1111/cas.13028

27486911

Domoto

Uehara

Bolidong

Minamoto

Glycogen synthase kinase 3β in cancer biology and treatment

Cells913882020

10.3390/cells9061388

32503133

Beurel

Grieco

Jope

Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases

Pharmacol Ther1481141312015

10.1016/j.pharmthera.2014.11.016

25435019

Turano

Costabile

Cerasuolo

Duraturo

Liccardo

Delrio

Pace

Rega

Dodaro

Milone

Characterisation of mesenchymal colon tumour-derived cells in tumourspheres as a model for colorectal cancer progression

Int J Oncol53237923962018

30272331

Kazi

Xiang

Yang

Delitto

Trevino

Jiang

RHY

Ayaz

Lawrence

Kennedy

Sebti

GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

Nat Commun951542018

10.1038/s41467-018-07644-6

30514931

Yoshino

Suzuki

Takahashi

Ishioka

Inhibition of invasion by glycogen synthase kinase-3 beta inhibitors through dysregulation of actin re-organisation via down-regulation of WAVE2

Biochem Biophys Res Commun4642752802015

10.1016/j.bbrc.2015.06.142

26116771

Chikano

Domoto

Furuta

Sabit

Kitano-Tamura

Pyko

Takino

Sai

Hayashi

Sato

Glycogen synthase kinase 3β sustains invasion of glioblastoma via the focal adhesion kinase, Rac1, and c-Jun N-terminal kinase-mediated pathway

Mol Cancer Ther145645742015

10.1158/1535-7163.MCT-14-0479

25504636

Kitano

Shimasaki

Chikano

Nakada

Hirose

Higashi

Ishigaki

Endo

Takino

Sato

Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy

PLoS One8e552892013

10.1371/journal.pone.0055289

23408967

Shakoori

Ougolkov

Zhang

Modarressi

Billadeau

Mai

Takahashi

Minamoto

Deregulated GSK3β activity in colorectal cancer: Its association with tumor cell survival and proliferation

Biochem Biophys Res Commun334136513732005

10.1016/j.bbrc.2005.07.041

16043125

Kawauchi

Chihama

Nabeshima

Hoshino

The in vivo roles of STEF/Tiam1, Rac1 and JNK in cortical neuronal migration

EMBO J22419042012003

10.1093/emboj/cdg413

12912917

Gayet

Zhou

Duval

Rolland

Hoang

Cottu

Hamelin

Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines

Oncogene20502550322001

10.1038/sj.onc.1204611

11526487

Ahmed

Eide

Eilertsen

Danielsen

Eknæs

Hektoen

Lind

Lothe

Epigenetic and genetic features of 24 colon cancer cell lines

Oncogenesis2e712013

10.1038/oncsis.2013.35

24042735

Mai

Miyashita

Shakoori

Zhang

Takahashi

Motoo

Kawakami

Minamoto

Detection of active fraction of GSK3β in cancer cells by nonradioisotopic in vitro kinase assay

Oncology712973052006

10.1159/000106429

17652946

Shakoori

Mai

Miyashita

Yasumoto

Takahashi

Ooi

Kawakami

Minamoto

Inhibition of GSK-3β activity attenuates proliferation of human colon cancer cells in rodents

Cancer Sci98138813932007

10.1111/j.1349-7006.2007.00545.x

17640304

Mai

Kawakami

Shakoori

Kyo

Miyashita

Yokoi

Jin

Shimasaki

Motoo

Minamoto

Deregulated glycogen synthase kinase 3β sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase

Clin Cancer Res15681068192009

10.1158/1078-0432.CCR-09-0973

19903789

Turunen

Tatti-Bugaeva

Lehti

Membrane-type matrix metalloproteases as diverse effectors of cancer progression

Biochim Biophys Acta Mol Cell Res1864197419882017

10.1016/j.bbamcr.2017.04.002

28390905

Ning

Gan

Shi

Meng

Effects of HDAC4 on IL-1β-induced matrix metalloproteinase expression regulated partially through the WNT3A/β-catenin pathway

Chin Med J (Engl)1349639702021

10.1097/CM9.0000000000001470

33840739

Tian

Cui

Clinical significance of heat shock proteins in gastric cancer following hyperthermia stress: Indications for hyperthermic intraperitoneal chemoperfusion therapy

Oncol Lett15938593912018

29946371

Grimmig

Moll

Kloos

Thumm

Moench

Callies

Kreckel

Vetterlein

Pelz

Polat

Upregulated heat shock proteins after hyperthermic chemotherapy point to induced cell survival mechanisms in affected tumor cells from peritoneal carcinomatosis

Cancer Growth Metastasis1011790644177305592017

10.1177/1179064417730559

29403306

Chen

Hsu

Chen

Lee

Huang

Secreted heat shock protein 90α induces colorectal cancer cell invasion through CD91/LRP-1 and NF-κB-mediated integrin αV expression

J Biol Chem28525458254662010

10.1074/jbc.M110.139345

20558745

Song

Guo

Song

Bai

Chen

Nie

HSP90-dependent PUS7 overexpression facilitates the metastasis of colorectal cancer cells by regulating LASP1 abundance

J Exp Clin Cancer Res401702021

10.1186/s13046-021-01951-5

33990203

Sims

McCready

Jay

Extracellular heat shock protein (HSP)70 and HSP90α assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion

PLoS One6e188482011

10.1371/journal.pone.0018848

21533148

Guo

Reigan

Siegel

Zirrolli

Gustafson

Ross

Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: Role of 17-AAG hydroquinone in heat shock protein 90 inhibition

Cancer Res6510006100152005

10.1158/0008-5472.CAN-05-2029

16267026

Bhat

Xue

Berg

Hellberg

Ormö

Nilsson

Radesäter

Jerning

Markgren

Borgegård

Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418

J Biol Chem27845937459452003

10.1074/jbc.M306268200

12928438

John

Paraiso

Rebecca

Cantini

Abel

Pagano

Meggers

Mathew

Krepler

Izumi

GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation

J Invest Dermatol132281828272012

10.1038/jid.2012.237

22810307

Hasan

Zhang

Gray

Williams

Miller

Allen

Lee

Kelly

Zhou

Phosphorylation regulates CAP1 (cyclase-associated protein 1) functions in the motility and invasion of pancreatic cancer cells

Sci Rep949252019

10.1038/s41598-019-41346-3

30894654

Zhou

Zhang

Ghai

Field

Phosphorylation of the cytoskeletal protein CAP1 controls its association with cofilin and actin

J Cell Sci127505250652014

25315833

Rom

Fan

Reichenbach

Dykstra

Ramirez

Persidsky

Glycogen synthase kinase 3β inhibition prevents monocyte migration across brain endothelial cells via Rac1-GTPase suppression and down-regulation of active integrin conformation

Am J Pathol181141414252012

10.1016/j.ajpath.2012.06.018

22863953

Yoeli-Lerner

Chin

Hansen

Toker

Akt/protein kinase B and glycogen synthase kinase-3β signaling pathway regulates cell migration through the NFAT1 transcription factor

Mol Cancer Res74254322009

10.1158/1541-7786.MCR-08-0342

19258413

Zhao

Zhang

EFEMP2 promotes colon cancer cell invasion and growth through the ERK1/2 signaling pathway

Int J Clin Exp Pathol128518562019

31933893

Rath

Stöckle

Roderfeld

Tschuschner

Graf

Roeb

Matrix metalloproteinase-13 is regulated by toll-like receptor-9 in colorectal cancer cells and mediates cellular migration

Oncol Lett24834882011

10.3892/ol.2011.276

22866107

Nakajima

Koizumi

Family with sequence similarity 107: A family of stress responsive small proteins with diverse functions in cancer and the nervous system (Review)

Biomed Rep23213252014

10.3892/br.2014.243

24748967

Kretzschmar

Schülke

Masana

Dürre

Müller

Bausch

Rein

The stress-inducible protein DRR1 exerts distinct effects on actin dynamics

Int J Mol Sci1939932018

10.3390/ijms19123993

30545002

Guo

Bian

Wang

Chen

Sun

FAM107B is regulated by S100A4 and mediates the effect of S100A4 on the proliferation and migration of MGC803 gastric cancer cells

Cell Biol Int41110311092017

10.1002/cbin.10816

28675500

Allgöwer

Kretz

von Karstedt

Wittau

Henne-Bruns

Lemke

Friend or foe: S100 proteins in cancer

Cancers (Basel)1220372020

10.3390/cancers12082037

32722137

Chen

Bresnick

O'Connor

Coupling S100A4 to rhotekin alters Rho signaling output in breast cancer cells

Oncogene32375437642013

10.1038/onc.2012.383

22964635

Huang

Wei

Chen

Chang

Silencing heat shock protein 27 inhibits the progression and metastasis of colorectal cancer (CRC) by maintaining the stability of stromal interaction molecule 1 (STIM1) proteins

Cells72622018

10.3390/cells7120262

30544747

Lin

Peng

Zhuang

Zhang

Wang

Hua

Heat shock proteins HSP70 and MRJ cooperatively regulate cell adhesion and migration through urokinase receptor

BMC Cancer146392014

10.1186/1471-2407-14-639

25175595

Moser

Lang

Kainz

Gaumann

Fichtner-Feigl

Koehl

Schlitt

Geissler

Stoeltzing

Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo

Mol Cancer Ther6286828782007

10.1158/1535-7163.MCT-07-0410

18025273

Hagn

Lagleder

Retzlaff

Rohrberg

Demmer

Richter

Buchner

Kessler

Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53

Nat Struct Mol Biol18108610932011

10.1038/nsmb.2114

21892170

Lacey

Linking hsp90′s role as an evolutionary capacitator to the development of cancer

Cancer Treat Res Commun281004002021

10.1016/j.ctarc.2021.100400

34023771

Dou

Chang

Hsp90 maintains the stability and function of the Tau phosphorylating kinase GSK3β

Int J Mol Sci851602007

10.3390/i8010060

Banz

Medová

Keogh

Furer

Zimmer

Candinas

Stroka

Hsp90 transcriptionally and post-translationally regulates the expression of NDRG1 and maintains the stability of its modifying kinase GSK3β

Biochim Biophys Acta1793159716032009

10.1016/j.bbamcr.2009.08.002

19682504

Tang

Chen

Fan

PGK1-coupled HSP90 stabilizes GSK3β expression to regulate the stemness of breast cancer stem cells

Cancer Biol Med194865032022

10.20892/j.issn.2095-3941.2020.0362

34403222

Muller

Ruckova

Halada

Coates

Hrstka

Lane

Vojtesek

C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances

Oncogene32310131102013

10.1038/onc.2012.314

22824801

Zhang

Zhao

β-Elemene promotes apoptosis induced by hyperthermia via inhibiting HSP70

Dis Markers202273130262022

35903296

Schwock

Dhani

Cao

Zheng

Clarkson

Radulovich

Navab

Horn

Hedley

Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts

Cancer Res69475047592009

10.1158/0008-5472.CAN-09-0454

19458065

Taiyab

Rao

ChM

HSP90 modulates actin dynamics: Inhibition of HSP90 leads to decreased cell motility and impairs invasion

Biochim Biophys Acta18132132212011

10.1016/j.bbamcr.2010.09.012

20883729

Liu

Xiang

Tian

Tan

Jing

Tian

Discovery of small-molecule inhibitors of the HSP90-calcineurin-NFAT pathway against glioblastoma

Cell Chem Biol26352365.e72019

10.1016/j.chembiol.2018.11.009

30639261

Chen

Zhang

Fang

Luo

Yin

Heat shock protein 90 regulates the stability of c-Jun in HEK293 Cells

Mol Cells242102142007

17978573

Stellas

El Hamidieh

Patsavoudi

Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits

BMC Cell Biol11512010

10.1186/1471-2121-11-51

20602761

Jia

Rao

Wang

Jin

Wang

Chen

Zhang

Guo

Chang

Liu

Inhibition of B16 murine melanoma metastasis and enhancement of immunity by fever-range whole body hyperthermia

Int J Hyperthermia272752852011

10.3109/02656736.2011.559613

21501029

Byun

Gwak

Kwon

Song

Shin

Yoo

Lee

Local recurrence of brain metastasis reduced by intra-operative hyperthermia treatment

Int J Hyperthermia351681752019

10.1080/02656736.2018.1488004

30293465

Zhao

Cai

Wei

Yin

Wang

Hao

Shen

Wang

Hyperthermic carbon dioxide pneumoperitoneum reinforces the inhibition of 5-FU on the proliferation and invasion of colon cancer

Oncol Rep374925002017

10.3892/or.2016.5229

27840981

Kumar

Stokes

IIISingh

Scissum Gunn

Acharya

Manne

Mishra

Targeting HSP70: A possible therapy for cancer

Cancer Lett3741561662016

10.1016/j.canlet.2016.01.056

26898980

Kryeziu

Bruun

Guren

Sveen

Lothe

Combination therapies with HSP90 inhibitors against colorectal cancer

Biochim Biophys Acta Rev Cancer18712402472019

10.1016/j.bbcan.2019.01.002

30708039

Zhou

Zhang

Sun

Targeted near infrared hyperthermia combined with immune stimulation for optimized therapeutic efficacy in thyroid cancer treatment

Oncotarget7687868902016

10.18632/oncotarget.6901

26769848

Vriend

LEM

van den Tempel

Oei

L'Acosta

Pieterson

Franken

NAP

Kanaar

Krawczyk

Boosting the effects of hyperthermia-based anticancer treatments by HSP90 inhibition

Oncotarget897490975032017

10.18632/oncotarget.22142

29228626

Daunys

Matulis

Petrikaitė

Synergistic activity of HSP90 inhibitors and anticancer agents in pancreatic cancer cell cultures

Sci Rep9161772019

10.1038/s41598-019-52652-1

31700053

Baran

Mert Ozupek

Yerli Tetik

Acar

Bekcioglu

Baskin

Difference between left-sided and right-sided colorectal cancer: A focused review of literature

Gastroenterology Res112642732018

10.14740/gr1062w

30116425

de Vries

Swets

Vahrmeijer

Hokland

Kuppen

The immunogenicity of colorectal cancer in relation to tumor development and treatment

Int J Mol Sci1710302016

10.3390/ijms17071030

27367680

Picard

Verschoor

Pawelec

Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer

Front Immunol113692020

10.3389/fimmu.2020.00369

32210966

Zhang

Wang

Lou

Feng

Integrated analysis of oncogenic networks in colorectal cancer identifies GUCA2A as a molecular marker

Biochem Res Int201964694202019

10.1155/2019/6469420

31467713

Mah

Thurnherr

Chow

Chung

Ooi

Toh

Teh

Saunthararajah

Lee

Methylation profiles reveal distinct subgroup of hepatocellular carcinoma patients with poor prognosis

PLoS One9e1041582014

10.1371/journal.pone.0104158

25093504

Song

Tiirikainen

Kwee

Okimoto

Wong

Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma

PLoS One8e557612013

10.1371/journal.pone.0055761

23437062

Kan

Chai

Chen

DNA methylation profiling identifies potentially significant epigenetically-regulated genes in glioblastoma multiforme

Oncol Lett18167916882019

31423235

Parameswaran

Ramakrishnan

Moreton

Xia

Hou

Lee

Gupta

deLima

Beck

Wald

Repression of GSK3 restores NK cell cytotoxicity in AML patients

Nat Commun7111542016

10.1038/ncomms11154

27040177

Cichocki

Valamehr

Bjordahl

Zhang

Rezner

Rogers

Gaidarova

Moreno

Tuininga

Dougherty

GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity

Cancer Res77566456752017

10.1158/0008-5472.CAN-17-0799

28790065

Noh

Son

Jung

Kang

Choi

Park

Glycogen synthase kinase-3β (GSK-3β) inhibition enhances dendritic cell-based cancer vaccine potency via suppression of interferon-γ-induced indoleamine 2,3-dioxygenase expression

J Biol Chem29012394124022015

10.1074/jbc.M114.628578

25814664

Taylor

Harker

Chanthong

Stevenson

Zuniga

Rudd

Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8(+) cytolytic T cell responses

Immunity442742862016

10.1016/j.immuni.2016.01.018

26885856

Grassilli

Narloch

Federzoni

Ianzano

Pisano

Giovannoni

Romano

Masiero

Leone

Bonin

Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy

Clin Cancer Res19382038312013

10.1158/1078-0432.CCR-12-3289

23729362

Figure 1.

Analysis of HITS overexpression or knockdown effects on GSK3β. (A-C) Western blotting analysis of HCT 116, RKO and SW480 colon cancer cells transfected with pEGFP (Ct) or pCAG-HITS-IRES-EGFP (Oexp) vector. (A) Expression of β-tubulin was monitored as the loading control. (B) Level of pGSK3β^S9 was normalized to the amount of GSK3β. (C) Relative level of GSK3β expression was normalized to the β-tubulin expression in the same cells. (D) Western blotting analysis of the levels of pGSK3β^S9 and GSK3β expression in HCT 116 cells transfected with control stealth siRNA (Ct), HITS-siRNA#1 (#1) or HITS-siRNA#2 (#2). Expression of β-tubulin was monitored as the loading control. The levels of (E) pGSK3β^S9/GSK3β and (F) pGSK3β/β-tubulin were normalized. The number of replicates is indicated in parenthesis in each panel. *P<0.05 and **P<0.01 compared with Ct group. HITS, heat shock-inducible tumor small protein; GSK3β, glycogen synthase kinase-3β; p, phosphorylated; EGFP, enhanced green fluorescent protein; S, serine; siRNA, short interfering RNA; Oexp, overexpression.

Figure 2.

HS effects on HITS transcription and GSK3β protein in HCT 116 cells. (A) Relative levels of HITS mRNA at several time points following treatment with HS compared with those in the untreated Ct cells. (B) Western blotting and subsequent statistical analysis of the protein levels of (C) pGSK3β^S9/GSK3β and (D) GSK3β/β-tubulin at several time points following treatment with HS compared with those in the untreated Ct cells. (E) Western blotting and subsequent statistical analysis of the protein levels of (F) pGSK3β^S9/GSK3β and (G) GSK3β/β-tubulin in cells transfected with control siRNA (Ct), HITS-siRNA#1 (#1) or HITS-siRNA#2 (#2), followed by HS and measured after 24 h. (B and E) Expression of β-tubulin was monitored as the loading control. Relative levels of (C and F) pGSK3β^S9 and (D and G) GSK3β expression in each sample were normalized to the amounts of GSK3β and β-tubulin, respectively. The number of replicates is indicated in parenthesis in each panel. *P<0.05 and **P<0.01 compared against respective Ct groups. HITS, heat shock-inducible tumor small protein; GSK3β, glycogen synthase kinase-3β; HS, heat shock; Ct, control; p, phosphorylated; siRNA, short interfering RNA.

Figure 3.

Effects of HITS on the migration and the proliferation of HCT 116 cells. (A and B) Wound healing assay was performed to compare the migration of cells transfected with pEGFP (Ct) or pCAG-HITS-IRES-EGFP (Oexp) vector. (A) Representative of bright field images (upper panels) and fluorescence images (lower panels) showing GFP-positive cells. (B) Comparison of the WH rate between cells transfected with pEGFP (Ct) or pCAG-HITS-IRES-EGFP (Oexp) vector. (C) Comparison of cell survival measured using the MTT assay between cells transfected with pEGFP (Ct) or pCAG-HITS-IRES-EGFP (Oexp) vector. (D) Comparative semi-quantitative RT-PCR analysis of MMP-3 and MMP-13 mRNA expression in HCT 116 cells transfected with pEGFP (Ct) or pCAG-HITS-IRES-EGFP vector (Oexp). Expression of HITS mRNA was normalized by TBP amplified as an internal control. (E and F) Western blotting analysis of MMP-3 and MMP-13 protein levels in cells transfected with pEGFP (Ct) or pCAG-HITS-IRES-EGFP (Oexp) vector. Expression of β-tubulin was monitored as the loading control (E). The number of replicates is indicated in parenthesis in each panel. *P<0.05 and **P<0.01 compared with Ct group. HITS, heat shock-inducible tumor small protein; EGFP, enhanced green fluorescent protein; WH, wound healing; RT-PCR, reverse transcription PCR; TBP, TATA-box binding protein.

Figure 4.

Effect of HITS on the migration of HCT 116 cells after HS. (A) Wound healing assay shows the migration of cells treated with HS compared with that in control cells (without HS; Ct). The left panels show the representative bright field images of the cells. The right panel shows the WH rate. (B-D) Effects of HITS knockdown (HITS-siRNA#1 and HITS-siRNA#2) alone or siRNA treatment in combination with 17-AAG (0.5 µM) or AR-A014418 (20 µM) on the migration of cells treated with HS for 1 h. (B) Schematic timeline of the experiment shown in (C) and (D). Each wound gap was made using a plastic insert that was placed on each well 25 h before starting the wound healing assay. (C) Representative bright field images of cells with the respective treatments. (D) Comparison of the WH rate between cells treated as indicated. WH rate of cells treated with inhibitors were compared with that of control cells transfected with control siRNA and were statistically significant as indicated by umbrella lines. The number of replicates is indicated in parenthesis in each panel. *P<0.05 and **P<0.01 compared with Ct; otherwise statistically insignificant. HS, heat shock; WH, wound healing; siRNA, short interfering RNA; Ct, control; HITS, heat shock-inducible tumor small protein.

Figure 5.

Schematic representation of the hypothetical pro- and anti-migratory pathways activated by heat shock in cancer cells. HITS, heat shock-inducible tumor small protein; HSP, heat shock protein; GSK3β, glycogen synthase kinase-3β; FAK, focal adhesion kinase; CAP1, adenylyl cyclase-associated protein 1; GEF, guanine nucleotide-exchange factor; JNK, c-Jun N-terminal kinase; NFAT, nuclear factor of activated T cells.